ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 000289

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain

Identifieur interne : 000289 ( PascalFrancis/Curation ); précédent : 000288; suivant : 000290

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain

Auteurs : Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Feger [France]

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:02-0176575

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Riluzole, Noyau sousthalamique, Neurone dopaminergique, Excitotoxicité, Pathologie expérimentale, Mécanisme action, Traitement, Animal, Rat, Chimiothérapie, Neuroprotecteur, Benzothiazole, Inhibiteur, Canal ionique, Sodium.
Wicri :
- topic : Sodium.

English descriptors

KwdEn :
- Animal, Benzothiazole, Chemotherapy, Dopaminergic neuron, Excitotoxicity, Experimental disease, Inhibitor, Ionic channel, Mechanism of action, Neuroprotective agent, Parkinson disease, Rat, Riluzole, Sodium, Subthalamic nucleus, Treatment.

Abstract

An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6-OHDA-induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain`
A11	`01`	`1`		`@1 HASSANI (Oum-Kaltoum)`
A11	`02`	`1`		`@1 MOUROUX (Mireille)`
A11	`03`	`1`		`@1 BOHME (Georg Andrees)`
A11	`04`	`1`		`@1 STUTZMANN (Jean-Marie)`
A11	`05`	`1`		`@1 FEGER (Jean)`
A14	`01`			`@1 Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 5 aut.`
A14	`02`			`@1 Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris @3 FRA @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 INSERM U-289, Hospital de la Salpêtrière @2 Paris @3 FRA @Z 5 aut.`
A20				`@1 1110-1114`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000094252170140`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 35 ref.`
A47	`01`	`1`		`@0 02-0176575`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6-OHDA-induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons.
C02	`01`	`X`		`@0 002B02B10`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Riluzole @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Riluzole @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Riluzol @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Noyau sousthalamique @5 07`
C03	`03`	`X`	`ENG`	`@0 Subthalamic nucleus @5 07`
C03	`03`	`X`	`SPA`	`@0 Núcleo subtalámico @5 07`
C03	`04`	`X`	`FRE`	`@0 Neurone dopaminergique @5 10`
C03	`04`	`X`	`ENG`	`@0 Dopaminergic neuron @5 10`
C03	`04`	`X`	`SPA`	`@0 Neurona dopaminérgica @5 10`
C03	`05`	`X`	`FRE`	`@0 Excitotoxicité @5 13`
C03	`05`	`X`	`ENG`	`@0 Excitotoxicity @5 13`
C03	`05`	`X`	`SPA`	`@0 Exitotoxicidad @5 13`
C03	`06`	`X`	`FRE`	`@0 Pathologie expérimentale @5 16`
C03	`06`	`X`	`ENG`	`@0 Experimental disease @5 16`
C03	`06`	`X`	`SPA`	`@0 Patología experimental @5 16`
C03	`07`	`X`	`FRE`	`@0 Mécanisme action @5 17`
C03	`07`	`X`	`ENG`	`@0 Mechanism of action @5 17`
C03	`07`	`X`	`SPA`	`@0 Mecanismo acción @5 17`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 18`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 18`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 18`
C03	`09`	`X`	`FRE`	`@0 Animal @5 20`
C03	`09`	`X`	`ENG`	`@0 Animal @5 20`
C03	`09`	`X`	`SPA`	`@0 Animal @5 20`
C03	`10`	`X`	`FRE`	`@0 Rat @5 21`
C03	`10`	`X`	`ENG`	`@0 Rat @5 21`
C03	`10`	`X`	`SPA`	`@0 Rata @5 21`
C03	`11`	`X`	`FRE`	`@0 Chimiothérapie @5 23`
C03	`11`	`X`	`ENG`	`@0 Chemotherapy @5 23`
C03	`11`	`X`	`SPA`	`@0 Quimioterapia @5 23`
C03	`12`	`X`	`FRE`	`@0 Neuroprotecteur @5 24`
C03	`12`	`X`	`ENG`	`@0 Neuroprotective agent @5 24`
C03	`12`	`X`	`SPA`	`@0 Neuroprotector @5 24`
C03	`13`	`X`	`FRE`	`@0 Benzothiazole @5 27`
C03	`13`	`X`	`ENG`	`@0 Benzothiazole @5 27`
C03	`13`	`X`	`SPA`	`@0 Benzotiazol @5 27`
C03	`14`	`X`	`FRE`	`@0 Inhibiteur @5 35`
C03	`14`	`X`	`ENG`	`@0 Inhibitor @5 35`
C03	`14`	`X`	`SPA`	`@0 Inhibidor @5 35`
C03	`15`	`X`	`FRE`	`@0 Canal ionique @5 36`
C03	`15`	`X`	`ENG`	`@0 Ionic channel @5 36`
C03	`15`	`X`	`SPA`	`@0 Canal iónico @5 36`
C03	`16`	`X`	`FRE`	`@0 Sodium @2 NC @5 77`
C03	`16`	`X`	`ENG`	`@0 Sodium @2 NC @5 77`
C03	`16`	`X`	`SPA`	`@0 Sodio @2 NC @5 77`
C07	`01`	`X`	`FRE`	`@0 Toxicité`
C07	`01`	`X`	`ENG`	`@0 Toxicity`
C07	`01`	`X`	`SPA`	`@0 Toxicidad`
C07	`02`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`04`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`07`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`08`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`08`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`08`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`09`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`09`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`09`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`10`	`X`	`FRE`	`@0 Encéphale @5 53`
C07	`10`	`X`	`ENG`	`@0 Brain (vertebrata) @5 53`
C07	`10`	`X`	`SPA`	`@0 Encéfalo @5 53`
N21				`@1 098`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001147

Links to Exploration step

Pascal:02-0176575

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain</title>
<author><name sortKey="Hassani, Oum Kaltoum" sort="Hassani, Oum Kaltoum" uniqKey="Hassani O" first="Oum-Kaltoum" last="Hassani">Oum-Kaltoum Hassani</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mouroux, Mireille" sort="Mouroux, Mireille" uniqKey="Mouroux M" first="Mireille" last="Mouroux">Mireille Mouroux</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Bohme, Georg Andrees" sort="Bohme, Georg Andrees" uniqKey="Bohme G" first="Georg Andrees" last="Bohme">Georg Andrees Bohme</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Stutzmann, Jean Marie" sort="Stutzmann, Jean Marie" uniqKey="Stutzmann J" first="Jean-Marie" last="Stutzmann">Jean-Marie Stutzmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Feger">Jean Feger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>INSERM U-289, Hospital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0176575</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 02-0176575 INIST</idno>
<idno type="RBID">Pascal:02-0176575</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001147</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000289</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain</title>
<author><name sortKey="Hassani, Oum Kaltoum" sort="Hassani, Oum Kaltoum" uniqKey="Hassani O" first="Oum-Kaltoum" last="Hassani">Oum-Kaltoum Hassani</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mouroux, Mireille" sort="Mouroux, Mireille" uniqKey="Mouroux M" first="Mireille" last="Mouroux">Mireille Mouroux</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Bohme, Georg Andrees" sort="Bohme, Georg Andrees" uniqKey="Bohme G" first="Georg Andrees" last="Bohme">Georg Andrees Bohme</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Stutzmann, Jean Marie" sort="Stutzmann, Jean Marie" uniqKey="Stutzmann J" first="Jean-Marie" last="Stutzmann">Jean-Marie Stutzmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Feger">Jean Feger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>INSERM U-289, Hospital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Benzothiazole</term>
<term>Chemotherapy</term>
<term>Dopaminergic neuron</term>
<term>Excitotoxicity</term>
<term>Experimental disease</term>
<term>Inhibitor</term>
<term>Ionic channel</term>
<term>Mechanism of action</term>
<term>Neuroprotective agent</term>
<term>Parkinson disease</term>
<term>Rat</term>
<term>Riluzole</term>
<term>Sodium</term>
<term>Subthalamic nucleus</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Riluzole</term>
<term>Noyau sousthalamique</term>
<term>Neurone dopaminergique</term>
<term>Excitotoxicité</term>
<term>Pathologie expérimentale</term>
<term>Mécanisme action</term>
<term>Traitement</term>
<term>Animal</term>
<term>Rat</term>
<term>Chimiothérapie</term>
<term>Neuroprotecteur</term>
<term>Benzothiazole</term>
<term>Inhibiteur</term>
<term>Canal ionique</term>
<term>Sodium</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Sodium</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6-OHDA-induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HASSANI (Oum-Kaltoum)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MOUROUX (Mireille)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BOHME (Georg Andrees)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>STUTZMANN (Jean-Marie)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FEGER (Jean)</s1>
</fA11>
<fA14 i1="01"><s1>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>INSERM U-289, Hospital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>1110-1114</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000094252170140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>35 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0176575</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6-OHDA-induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Riluzole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Riluzole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Riluzol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Noyau sousthalamique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Subthalamic nucleus</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Núcleo subtalámico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Neurone dopaminergique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopaminergic neuron</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Excitotoxicité</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Excitotoxicity</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Exitotoxicidad</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pathologie expérimentale</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Experimental disease</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Patología experimental</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Mécanisme action</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Mechanism of action</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Mecanismo acción</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Animal</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Animal</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Animal</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Rat</s0>
<s5>21</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Rat</s0>
<s5>21</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Rata</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Benzothiazole</s0>
<s5>27</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Benzothiazole</s0>
<s5>27</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Benzotiazol</s0>
<s5>27</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Inhibiteur</s0>
<s5>35</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Inhibitor</s0>
<s5>35</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Inhibidor</s0>
<s5>35</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Canal ionique</s0>
<s5>36</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Ionic channel</s0>
<s5>36</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Canal iónico</s0>
<s5>36</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Sodium</s0>
<s2>NC</s2>
<s5>77</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Sodium</s0>
<s2>NC</s2>
<s5>77</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Sodio</s0>
<s2>NC</s2>
<s5>77</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Toxicité</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Toxicity</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Toxicidad</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>53</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>53</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>53</s5>
</fC07>
<fN21><s1>098</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000289 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000289 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:02-0176575
   |texte=   Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri